MA41124A - Compositions en suspension à libération prolongée à rétention gastrique - Google Patents

Compositions en suspension à libération prolongée à rétention gastrique

Info

Publication number
MA41124A
MA41124A MA041124A MA41124A MA41124A MA 41124 A MA41124 A MA 41124A MA 041124 A MA041124 A MA 041124A MA 41124 A MA41124 A MA 41124A MA 41124 A MA41124 A MA 41124A
Authority
MA
Morocco
Prior art keywords
extended
gastric retention
suspension compositions
release suspension
release
Prior art date
Application number
MA041124A
Other languages
English (en)
Inventor
Paras P Jain
Suchitra Kaushik
Ashish Kumar
Vinay Kumar
Romi Barat Singh
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MA41124A publication Critical patent/MA41124A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA041124A 2014-12-05 2015-04-30 Compositions en suspension à libération prolongée à rétention gastrique MA41124A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3553DE2014 2014-12-05

Publications (1)

Publication Number Publication Date
MA41124A true MA41124A (fr) 2017-10-10

Family

ID=56091086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041124A MA41124A (fr) 2014-12-05 2015-04-30 Compositions en suspension à libération prolongée à rétention gastrique

Country Status (10)

Country Link
US (1) US20180008539A1 (fr)
EP (1) EP3226839A4 (fr)
JP (1) JP2017536404A (fr)
AU (1) AU2015356781A1 (fr)
BR (1) BR112017011922A2 (fr)
CA (1) CA2969820A1 (fr)
MA (1) MA41124A (fr)
MX (1) MX2017007299A (fr)
RU (1) RU2017123366A (fr)
WO (1) WO2016087952A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
EP4755373A1 (fr) * 2016-09-09 2026-06-10 Azurity Pharmaceuticals, Inc. Suspensions et diluants de metronidazole et de baclofene
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US12514818B2 (en) * 2017-12-18 2026-01-06 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
AU2018388577B2 (en) * 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
WO2020061308A1 (fr) * 2018-09-21 2020-03-26 Kashiv Biosciences, Llc Compositions à libération prolongée comprenant du trihexyphénidyle
KR20200053746A (ko) 2018-11-09 2020-05-19 (주)아모레퍼시픽 졸-겔 조성물
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
US20220031623A1 (en) * 2018-12-18 2022-02-03 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a methylcellulose
US20220062305A1 (en) * 2018-12-18 2022-03-03 DDP Specialty Electronic Materials US, Inc. Sustained release composition comprising an ethylcellulose
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
EP3968980A1 (fr) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Traitement de symptômes nocturnes et de l'akinésie matinale chez des sujets atteints de la maladie de parkinson
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
CN112516159B (zh) * 2020-12-03 2022-06-17 爱希（北京）国际咨询有限公司 一种含有硝酸盐的组合物、胃漂浮剂及制备方法和应用
US11154505B1 (en) 2021-02-03 2021-10-26 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising trihexyphenidyl
WO2022195476A1 (fr) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Dispositifs de rétention gastrique pour l'évaluation d'états intragastriques
CN112933055B (zh) * 2021-03-23 2023-01-13 安徽九华华源药业有限公司 帕利哌酮胃滞留片及其制备方法
MX2024006405A (es) * 2021-11-25 2024-06-05 Orexa B V Unidad de dosificacion oral gastrorretentiva que contiene un anestesico local.
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN117398380B (zh) * 2022-06-29 2026-06-30 威智医药股份有限公司 卡维地洛或其盐、组合物的新用途及该组合物和制备方法
JP2025525831A (ja) * 2022-08-02 2025-08-07 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー アルギネートをベースとする放出調節組成物
WO2024142002A1 (fr) 2022-12-29 2024-07-04 Renata Pharmaceuticals (Ireland) Limited Suspension pharmaceutique de nilotinib
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物
CN119074761B (zh) * 2024-09-10 2025-07-22 常州市儿童医院(常州市第六人民医院) 一种含铝碳酸镁和海藻多糖的制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
HK1040921B (en) * 1998-12-23 2005-12-30 Alza Corporation Dosage forms comprising porous particles
JP2004002320A (ja) * 2002-03-04 2004-01-08 Medorekkusu:Kk 生体内で相転移する液状マトリックスおよび液状経口製剤
JP4732696B2 (ja) * 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
CN101160126A (zh) * 2005-04-20 2008-04-09 默克公司 血管紧张肽ⅱ受体拮抗剂
CA2678367C (fr) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Compositions a liberation prolongee utilisant des matieres cireuses
WO2008122993A1 (fr) * 2007-04-09 2008-10-16 Panacea Biotec Limited Formulation de microparticules enrobées à libération contrôlée
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010011466A2 (fr) * 2008-06-27 2010-01-28 Otonomy, Inc. Compositions de modulation du snc à libération contrôlée et procédés de traitement des troubles otiques
WO2011107855A2 (fr) * 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Forme dosifiée sous forme de suspension liquide à libération prolongée pour une administration par voie orale
CA2947528C (fr) * 2014-05-01 2023-09-05 Sun Pharmaceutical Industries Limited Compositions en suspension a liberation prolongee

Also Published As

Publication number Publication date
RU2017123366A3 (fr) 2019-01-10
EP3226839A1 (fr) 2017-10-11
MX2017007299A (es) 2017-08-25
WO2016087952A1 (fr) 2016-06-09
RU2017123366A (ru) 2019-01-10
CA2969820A1 (fr) 2016-06-09
US20180008539A1 (en) 2018-01-11
AU2015356781A1 (en) 2017-06-29
EP3226839A4 (fr) 2018-07-11
JP2017536404A (ja) 2017-12-07
BR112017011922A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
MA44702A (fr) Compositions de suspension à libération prolongée
DK3731771T3 (da) V462033dk00
CL2018000524S1 (es) Golilla
EP3374114A4 (fr) Établi
EP3589248A4 (fr) Cryothérapies
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (fr) Inhibiteurs de magl à base de pyrazole
EP3588580A4 (fr) Diode schottky mos à tranchée
EP3340839A4 (fr) Oreiller
DK3351526T3 (da) Diisopentylterephthalat
EP3634397A4 (fr) Chromophores ir à base de polyméthine hétérocyclyle
EP3654852A4 (fr) Garrot
KR20180084876A (ko) 내플라즈마성 부재
DK3568655T3 (da) Rekuperator
EP3509417A4 (fr) Agencement flottant
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
DK3612237T3 (da) Genterapi
EP3611402A4 (fr) Servocylindre
DK3438103T3 (da) Griseofulvinforbindelse
EP3615471A4 (fr) Immunocapteur plasmo-photoélectronique
EP3684343C0 (fr) Superparticules améliorées
MA45305A (fr) Suspension améliorée
EP3669219C0 (fr) Réseau echelle
EP3490399A4 (fr) Raccord
DK3576686T3 (da) Brokbind